Dyno Therapeutics announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design.
Everything life does is controlled by biological sequences: DNA, RNA, and proteins. The capacity to design these sequences can drastically improve outcomes in healthcare and technology. Over the past decade, Dyno has pioneered an AI-powered approach to sequence design, creating some of the first in vivo-validated biologics using generative AI. Recently, Dyno’s proprietary generative AI methods yielded optimized capsid products that allow enhanced in vivo delivery of genetic therapies for Dyno’s partners, including the Dyno eCap™ 1 capsid in the eye and the Dyno bCap™ 1 capsid in the brain. Both have been validated through in vivo studies. Sequence-design algorithms become much more powerful when trained with appropriately large and diverse data sets and sufficiently fast and versatile computational resources. Dyno believes transformative sequence design capabilities can be brought within reach using its extensive proprietary datasets and the scale NVIDIA’s compute platform enables.
Dyno relies heavily on NVIDIA accelerated computing for its inference and design pipelines. NVIDIA will support the collaboration through its cloud infrastructure, software and the NVIDIA BioNeMo framework. These will enable Dyno to research and deploy advanced machine-learning models at a higher velocity for sequence design. Dyno’s machine learning scientists and engineers will work with NVIDIA AI experts to scale, enhance, and optimize Dyno’s AI-powered inference and search algorithms, serving them through NVIDIA NIM microservices and BioNeMo, both part of NVIDIA AI Enterprise.
“For billions of years, Darwinian evolution has been the world’s most powerful sequence design algorithm, but the resulting gene and genome sequences represent only a slim fraction of what we now know is possible to achieve. For decades, bioengineering progress has advanced primarily through mimicking this process in the lab. Dyno has demonstrated that a new route is possible by combining AI with high-throughput molecular experimentation in a self-reinforcing learning loop,” said Eric Kelsic, Ph.D., founder and Chief Executive Officer of Dyno Therapeutics. “Our work with NVIDIA will massively scale and improve this capability so that we can rapidly navigate sequence space at a pace matching revolutionary advances in modern computation, creating transformative medicines that help many more patients.”
Also Read: Sorcero Generative AI Platform Achieves Breakthrough in Patient Accessibility
“One of the greatest impacts of generative AI is its ability to revolutionize life sciences and healthcare,” said Rory Kelleher, Global Head of Business Development for Life Sciences at NVIDIA. “NVIDIA’s collaboration with Dyno will optimize and scale high-performance biological sequence design, helping to dramatically accelerate the pace of drug discovery and development.”
All patients can potentially benefit from the ability to design therapies based on biological sequences. As the diversity of life vividly displays the breadth of the sequence-based biological design space, improved sequence-design capabilities have the potential to create myriad new medicines with vast potential for life-changing impact. For this reason, Dyno was founded to apply advanced sequence design technologies to solve therapeutic challenges. Dyno’s team has been focused over the past decade on solving the challenge of in vivo delivery for genetic therapies by engineering optimized Adeno-associated virus (AAV) capsid sequences, and in doing so became a world leader in machine-guided sequence design and generative AI. The collaboration is made possible as a result of the insights and learnings generated by the Dyno team, including billions of in vivo sequence-function data points measured across millions of distinct capsid sequences, and the computational revolution being catalyzed by NVIDIA platforms.
Dyno’s team, accelerated by NVIDIA’s full-stack accelerated computing and AI expertise, will develop and apply AI models across numerous research areas including multi-property capsid optimization and design of novel AAV serotypes, while also generalizing these capabilities to a broader range of therapeutically relevant molecules. Dyno’s partners will benefit from the accelerated pace of Dyno’s research and development of new capsid products, as well as from computational capabilities that Dyno may offer to pharmaceutical partners through NVIDIA’s BioNeMo.
Source: BusinessWire
